Adagene Inc wrapped up its $139.73 million initial public offering, selling 7,354,000 American depositary shares at $19 each. The stock opened at $20.40 when trading began Tuesday and skyrocketed by more than 45% in early trading.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.61 |
|---|---|
| 52-week range | $1.21 - $4.38 |
| 50-day moving average | $2.69 |
| 200-day moving average | $2.63 |
| Wall St. target price | $9.15 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.72 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.61 from 2024-09-06
| 1 week (2024-08-30) | -6.79% |
|---|---|
| 1 month (2024-08-07) | 13.48% |
| 3 months (2024-06-07) | -12.41% |
| 6 months (2024-03-07) | -8.42% |
| 1 year (2023-09-07) | 86.43% |
|---|---|
| 2 years (2022-09-07) | 74.00% |
| 3 years (2021-09-07) | 16.48 |
| 5 years (2019-09-03) | N/A |
| Revenue TTM | $815,746 |
|---|---|
| Gross profit TTM | $10.2 million |
| Return on assets TTM | -19.59% |
| Return on equity TTM | -45.7% |
| Profit margin | 0% |
| Book value | $1.28 |
| Market Capitalization | $124 million |
TTM: trailing 12 months
We're not expecting Adagene Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Adagene Inc's shares have ranged in value from as little as $1.209 up to $4.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adagene Inc's is 0.664. This would suggest that Adagene Inc's shares are less volatile than average (for this exchange).
To put Adagene Inc's beta into context you can compare it against those of similar companies.
Adagene Inc. , a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China. .
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.